骨關節炎藥物市場 - 依藥物類型（黏稠補充劑、非類固醇抗發炎藥、鎮痛藥、皮質類固醇）、給藥途徑（口服、腸胃外）、解剖學、藥物、配銷通路和預測2024 - 2032

Osteoarthritis Drugs Market - By Drug Type (Viscosupplementation Agents, NSAIDs, Analgesics, Corticosteroids), By Route of Administration (Oral, Parenteral), By Anatomy, By Medication, By Distribution Channel & Forecast 2024 - 2032

出版日期: 2024年03月19日 | 出版商:

Global Market Insights Inc. | 英文 260 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

骨關節炎藥物市場規模預計從2024 年到2032 年將以6.9% 的複合年成長率擴大。需求。根據澳洲統計局的數據，2022年，澳洲約有370萬人患有關節炎。

藥物開發的重大突破，包括新療法和生物製劑的推出，正在促進產業創新。醫療保健專業人員和患者對骨關節炎早期診斷和治療重要性的認知不斷提高，也增加了骨關節炎藥物的吸引力。老年人口的不斷擴大，加上肥胖相關骨關節炎負擔的日益加重，正在為產品開發創造大量機會。越來越多的改善醫療保健服務和骨關節炎治療報銷政策的措施將進一步促進市場的發展。

骨關節炎藥物市場分為藥物類型、給藥途徑、解剖學、藥物、配銷通路和地區。

就藥物類型而言，由於骨關節炎患者對止痛藥物的需求增加，2024年至2032年間止痛藥市場規模將以7.1%的成長率成長。骨關節炎相關疼痛的普遍存在推動了對有效鎮痛藥物的需求，以控制症狀並改善患者的生活品質。非處方（OTC）鎮痛藥和處方藥的出現，加上藥物配方和給藥方法的進步，正在推動該細分市場的成長。

根據給藥途徑，由於口服藥物的便利性和患者的廣泛接受性，2024年至2032年口服骨關節炎藥物行業的複合年成長率預計為6.7%。與其他途徑相比，口服藥物給藥方便，患者依從性較高。包括片劑、膠囊和液體在內的多種口服製劑的可用性也為劑量和治療選擇提供了靈活性。

從地區來看，由於人口迅速老化以及生活型態改變導致骨關節炎盛行率不斷增加，預計2024年至2032年亞太地區骨關節炎藥物產業的年增率將達到7.5%。亞太地區不斷成長的醫療保健支出正在改善醫療保健服務的可近性，並提高人們對骨關節炎治療方案的認知。新療法的引入、藥物開發的進步以及政府為解決肌肉骨骼疾病負擔而採取的舉措也有利於區域市場的擴張。

主要動向：按地區
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 歐洲其他地區
亞太地區
- 日本
- 中國
- 印度
- 澳洲
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 中東和非洲其他地區

第 11 章：公司簡介

Anika Therapeutics
Assertio Holdings, Inc.
Bayer AG
Bioventus
Ferring Pharmaceuticals Inc.
GSK plc
Novartis AG
Pacira Pharmaceuticals, Inc
Pfizer Inc
Sanofi SA
Zimmer Biomet Holdings, Inc.

簡介目錄

Product Code: 8580

Osteoarthritis Drugs Market size is projected to expand at 6.9% CAGR from 2024 to 2032. The increasing prevalence of osteoarthritis due to aging population and sedentary lifestyles is fueling the demand for effective treatment options. As per the Australian Bureau of Statistics, in 2022, around 3.7 million people suffered from arthritis in Australia.

Significant breakthroughs in drug development, including the introduction of novel therapies and biologics are promoting innovations in the industry. The rising awareness about the importance of early diagnosis and treatment of osteoarthritis among healthcare professionals and patients is also increasing the appeal of osteoarthritis drugs. The expanding geriatric population, coupled with the growing burden of obesity-related osteoarthritis is creating numerous opportunities for product development. The growing initiatives to improve access to healthcare services and reimbursement policies for osteoarthritis treatments will further compliment the market progression.

The osteoarthritis drugs market is segregated into drug type, route of administration, anatomy, medication, distribution channel, and region.

In terms of drug type, the market size from the analgesics segment will grow at 7.1% growth rate between 2024 and 2032, due to the higher demand for pain relief medications among osteoarthritis patients. The prevalence of osteoarthritis-related pain is driving the need for effective analgesic drugs to manage symptoms and improve quality of life of patients. The availability of over-the-counter (OTC) analgesics and prescription medications, coupled with advancements in drug formulations and delivery methods is driving the segment growth.

Based on route of administration, the osteoarthritis drugs industry from the oral segment is slated to depict 6.7% CAGR from 2024 to 2032, on account of the convenience and widespread acceptance of oral medications among patients. Oral drugs offer ease of administration and greater patient compliance compared to other routes. The availability of a wide range of oral formulations, including tablets, capsules, and liquids is also providing flexibility in dosing and treatment options.

Regionally, the Asia Pacific osteoarthritis drugs industry is projected to expand at 7.5% CGR from 2024 to 2032, owing to the rapidly aging population and increasing prevalence of osteoarthritis due to lifestyle changes. The rising healthcare expenditure across APAC is improving access to healthcare services and expanding awareness about osteoarthritis treatment options. The introduction of novel therapies, advancements in drug development, and the launch of government initiatives to address the burden of musculoskeletal diseases are also favoring the regional market expansion.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Base estimates & calculations
1.3 Data collection
1.4 Forecast parameters
1.5 Data validation
1.6 Data sources
- 1.6.1 Primary
- 1.6.2 Secondary
  - 1.6.2.1 Paid sources
  - 1.6.2.2 Public sources

Chapter 2 Executive Summary

2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing geriatric population
  - 3.2.1.2 Increasing research & development activities and funding for osteoarthritis therapeutics
  - 3.2.1.3 High prevalence of osteoarthritis
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Side effects associated with drugs
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Porter's analysis
- 3.5.1 Supplier power
- 3.5.2 Buyer power
- 3.5.3 Threat of new entrants
- 3.5.4 Threat of substitutes
- 3.5.5 Industry rivalry
3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Company market share analysis
4.4 Competitive positioning matrix
4.5 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Drug Type, 2018 - 2032 ($ Million)

5.1 Key trends
5.2 Viscosupplementation agents
5.3 Nonsteroidal anti-inflammatory drugs
- 5.3.1 Naproxen
- 5.3.2 Aspirin
- 5.3.3 Diclofenac
- 5.3.4 Ibuprofen
- 5.3.5 Celecoxib
- 5.3.6 Meloxicam
- 5.3.7 Piroxicam
- 5.3.8 Ketoprofen
- 5.3.9 Other NSAIDs
5.4 Analgesics
- 5.4.1 Duloxetine
- 5.4.2 Acetaminophen
5.5 Corticosteroids
5.6 Other drug types

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2018 - 2032 ($ Million)

6.1 Key trends
6.2 Oral
6.3 Parenteral
6.4 Topical

Chapter 7 Market Estimates and Forecast, By Anatomy, 2018 - 2032 ($ Million)

7.1 Key trends
7.2 Ankle osteoarthritis
7.3 Hip osteoarthritis
7.4 Knee osteoarthritis
7.5 Shoulder osteoarthritis
7.6 Other anatomies

Chapter 8 Market Estimates and Forecast, By Medication, 2018 - 2032 ($ Million)

8.1 Key trends
8.2 Prescription drugs
8.3 Over-the-counter drugs

Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2018 - 2032 ($ Million)

9.1 Key trends
9.2 Hospital pharmacies
9.3 Retail pharmacies
9.4 Online pharmacy

Chapter 10 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Million)

10.1 Key trends, by region
10.2 North America
- 10.2.1 U.S.
- 10.2.2 Canada
10.3 Europe
- 10.3.1 Germany
- 10.3.2 UK
- 10.3.3 France
- 10.3.4 Spain
- 10.3.5 Italy
- 10.3.6 Rest of Europe
10.4 Asia Pacific
- 10.4.1 Japan
- 10.4.2 China
- 10.4.3 India
- 10.4.4 Australia
- 10.4.5 Rest of Asia Pacific
10.5 Latin America
- 10.5.1 Brazil
- 10.5.2 Mexico
- 10.5.3 Rest of Latin America
10.6 Middle East and Africa
- 10.6.1 South Africa
- 10.6.2 Saudi Arabia
- 10.6.3 Rest of Middle East and Africa